GSA Capital Partners LLP purchased a new stake in shares of Exagen Inc. (NASDAQ:XGN – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 214,721 shares of the company’s stock, valued at approximately $998,000. GSA Capital Partners LLP owned approximately 0.89% of Exagen as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Bridgeway Capital Management LLC boosted its position in shares of Exagen by 10.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock worth $194,000 after purchasing an additional 2,600 shares in the last quarter. Truvestments Capital LLC boosted its position in shares of Exagen by 109.5% during the fourth quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock valued at $38,000 after buying an additional 3,225 shares during the last quarter. State Street Corp boosted its holdings in shares of Exagen by 6.9% during the 4th quarter. State Street Corp now owns 71,256 shares of the company’s stock valued at $433,000 after acquiring an additional 4,600 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Exagen in the 1st quarter worth approximately $25,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Exagen by 3.9% in the third quarter. Russell Investments Group Ltd. now owns 229,115 shares of the company’s stock worth $2,518,000 after acquiring an additional 8,499 shares during the period. Institutional investors own 75.25% of the company’s stock.
Exagen Trading Up 0.6%
XGN stock opened at $6.70 on Tuesday. The company has a market capitalization of $162.34 million, a PE ratio of -8.27 and a beta of 2.05. The firm’s 50-day moving average is $4.95 and its 200 day moving average is $3.97. Exagen Inc. has a 12 month low of $2.59 and a 12 month high of $12.23. The company has a debt-to-equity ratio of 1.96, a current ratio of 3.18 and a quick ratio of 3.18.
Analyst Upgrades and Downgrades
XGN has been the subject of several recent research reports. Canaccord Genuity Group cut their target price on shares of Exagen from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, April 20th. B. Riley Financial reiterated a “buy” rating and set a $12.00 target price (up from $8.00) on shares of Exagen in a research report on Wednesday, August 5th. TD Cowen lifted their price target on shares of Exagen from $8.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. BTIG Research lifted their price objective on Exagen from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Roth Capital initiated coverage on shares of Exagen in a report on Wednesday, June 24th. They issued a “buy” rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Exagen has an average rating of “Moderate Buy” and a consensus price target of $9.62.
Get Our Latest Stock Report on Exagen
About Exagen
Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.
The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.
Featured Stories
- Five stocks we like better than Exagen
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Want to see what other hedge funds are holding XGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exagen Inc. (NASDAQ:XGN – Free Report).
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
